natgillin/translations-raw huggingface dataset:
A pharmaceutical composition comprising the compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 25, ili njegovu farmaceutski prihvatljivu sol ili njegov solvat i farmaceutski prihvatljiv nosač.
A commercial package comprising the pharmaceutical composition according to claim 26 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for the treatment or prophylaxis of a disease selected from anemia and renal anemia. 
Komercijalno pakiranje koje sadrži farmaceutski sastav prema patentnom zahtjevu 26 i pisano uputstvo u vezi sa njim, pri čemu je u pisanom uputstvu navedeno da se farmaceutski sastav može ili treba koristiti u liječenju profilakse bolesti izabrane od anemije i bubrežne anemije.
The pharmaceutical composition of claim 3 taking the form of a liquid, emulsion, solid, aerosol or gas. 
Farmaceutski pripravak prema zahtjevu 2, naznačen time, da je obliku tekućine, krutine, emulzija, aerosola ili plina.
natural or synthetically derived refinements of natural components of bacteria such as Freund's adjuvant and its derivatives, muramyldipeptide (MDP) derivatives, CpG, monophosphoryl lipid A; 
prirodni ili sintetski dobivene prerađevine prirodnih sastojaka bakterija, kao što su Freundov adjuvans i njegovi derivati, derivati muramildipeptida (MDP), CpG, monofosforil lipid A;
bacterial toxins and toxoids. 
bakterijski toksini i toksoidi.
The formulation according to claim 7 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, imiqimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Smjesa prema zahtjevu 37 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense (besmislene) RNA, Imiqimod, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantadina.
A pharmaceutical composition according to claim 15 or 16, wherein the sufficient dose of oxycodone is 5 to 400 mg. 
Farmaceutski oblik prema zahtjevu 15 ili 16, gdje je dovoljna doza oksikodona 5 do 400 mg.
Amisulpride for use in the therapy of a condition which is chemotherapy-induced or radiation-induced nausea and vomiting. 
Amisulprid za uporabu u liječenju stanja koje je mučnina i povraćanje izazvano kemoterapijom.
A cutting tool assembly (14) adapted to be coupled to a cutter head (12) for manufacture of a gear, the cutting tool assembly (14) comprising: 
Uređaj rezačkog pribora (14), koji je prilagođen za spajanje na rezačku glavu (12) kako bi se načinio zupčanik, pri čemu taj uređaj rezačkog pribora (14) obuhvaća:
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor according to claim 1, wherein the tumors are islet cell tumors, APUDomas, insulinomas, glucagonomas, nonfunctioning pancreatic NETs, pancreatic NETs associated with hypercalcemia, gastrinomas, VIPomas, somatostatinomas, or GRFomas. 
-O-(2-hidroksietil)-rapamicin za uporabu u liječenju neuroendokrinog tumora pankreasa prema zahtjevu 1, naznačen time, da tumori su tumori stanica-otočića, APUDomi, inzulinomi, glukagonomi, nefunkcionalni NET-ovi pankreasa, NET-ovi pankreasa povezani s hiperkalcemijom, gastrinomi, VIPomi, somatostatinomi ili GRFomi.
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor invasiveness according to claim 8, wherein metastatic spread is prevented or growth of micrometastasis inhibited. 
-O-(2-hidroksietil)-rapamicin za uporabu u obradi invazivnosti neuroendokrinog tumora pankreasa prema zahtjevu 8, naznačen time, da se sprečava širenje metastaza ili se inhibira rast mikrometastaza.
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor according to any one of claims 1, 2, or 4 to 7, or neuroendocrine tumor invasiveness according to claim 8, wherein 40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor or neuroendocrine tumor invasiveness is in a combination with at least one second drug substance. 
-O-(2-hidroksietil)-rapamicin za uporabu u liječenju neuroendokrinog tumora pankreasa prema jednom od zahtjeva 1, 2 ili 4 do 7, ili u obradi invazivnosti neuroendokrinog tumora pankreasa prema zahtjevu 8, naznačen time, da se 40-O-(2-hidroksietil)-rapamicin koji se upotrebljava u liječenju neuroendokrinog tumora pankreasa ili u obradi invazivnosti neuroendokrinog tumora pankreasa, nalazi u kombinaciji s najmanje jednom dodatnom ljekovitom tvari.
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor or pancreatic neuroendocrine tumor invasiveness according to claim 10, wherein at least one second drug substance is somatostatin or somatostatin analogue. 
-O-(2-hidroksietil)-rapamicin za uporabu u liječenju neuroendokrinog tumora pankreasa ili u obradi invazivnosti neuroendokrinog tumora pankreasa prema zahtjevu 10, naznačen time, da najmanje jedna dodatna ljekovita tvar je somatostatin ili analog somatostatina.
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor or pancreatic neuroendocrine tumor invasiveness according to claim 11, wherein at least one second drug substance is octreotide. 
-O-(2-hidroksietil)-rapamicin za uporabu u liječenju neuroendokrinog tumora pankreasa ili u obradi invazivnosti neuroendokrinog tumora pankreasa prema zahtjevu 11, naznačen time, da najmanje jedna dodatna ljekovita tvar je oktreotid.
40-O-(2-hydroxyethyl)-rapamycin for use in a treatment of pancreatic neuroendocrine tumor according to claim 3, wherein 40-O-(2-hydroxyethyl)-rapamycin is administered in combination with octreotide and the tumor is secretory pancreatic tumor. 
-O-(2-hidroksietil)-rapamicin za uporabu u liječenju neuroendokrinog tumora pankreasa prema zahtjevu 3, naznačen time, da se 40-O-(2-hidroksietil)-rapamicin primjenjuje u kombinaciji s oktreotidom, a tumor je sekrecijski tumor pankreasa.
A method for detecting lung, breast or bladder cancer according to claim 1 or 2, comprising: 
Postupak otkrivanja raka pluća, dojke ili mjehura prema zahtjevu 1 ili 2, obuhvaća:
treating the genomic DNA of a), or a fragment thereof, with one or more reagents to convert cytosine bases that are unmethylated in the 5-position thereof to uracil or to another base that is detectably dissimilar to cytosine in terms of hybridization properties; 
obradu genomske DNA iz a), ili njezinog fragmenta, s jednim ili više reagenasa radi pretvorbe citozin baza koje nisu metilirane na svom položaju 5 u uracil ili drugu bazu koja za otkrivanje nije slična citozinu u vidu svojstava hibridizacije;
A method for detecting lung, breast or bladder cancer according to claim 1, comprising: 
Postupak otkrivanja raka pluća, dojke ili mjehura prema zahtjevu 1, obuhvaća:
Use according to claim 6, wherein said nucleic acid comprises at least 50 contiguous nucleotides. 
Uporaba prema zahtjevu 6, gdje ta nukleinska kiselina obuhvaća barem 50 dodirnih nukleotida.
A gypsum-based wallboard, comprising an inorganic phase of gypsum and an organic phase, wherein the organic phase is formed of a strengthening additive comprising a cationic acid-modified starch ionically cross-linked by a crosslinking additive in situ, the crosslinking additive being an anionic starch, wherein the amount of crosslinking additive is 75wt% or less based on the total weight of the strengthening additive and crosslinking additive, and wherein the cross-linked strengthening additive forms a polymer network and the ionic interactions between the strengthening additive and the crosslinking additive substantially strengthen the wallboard. 
Ploča na bazi gipsa, naznačena time, da obuhvaća anorgansku fazu od gipsa i organsku fazu, gdje je organska faza formirana od aditiva za učvršćivanje koji sadrži kiselinski modificirani kationski škrob ionski unakrsno povezan pomoću aditiva za unakrsno povezivanje in situ, pri čemu je aditiv za unakrsno povezivanje anionski škrob, dok količina aditiva za unakrsno povezivanje iznosi 75 masenih % ili manje temeljem ukupne mase aditiva za učvršćivanje i aditiva za unakrsno povezivanje, pri čemu unakrsno povezani aditiv za učvršćivanje tvori mrežu polimera te ionske interakcije između aditiva za učvršćivanje i aditiva za unakrsno povezivanje bitno ojačavaju ploču.
The gypsum-based wall board of claim 1, wherein the cationic starch has a degree of substitution selected in a range from 0.5 to 3 wt%. 
Ploča na bazi gipsa prema zahtjevu 1, naznačena time, da kationski škrob ima mjeru supstitucije odabranu u rasponu od 0,5 do 3 masenih %.
The gypsum-based wallboard of claim 1, wherein the cationic starch is a starch ether. 
Ploča na bazi gipsa prema zahtjevu 1, naznačena time, da kationski škrob je škrobni eter.
The gypsum-based wallboard of claim 3, wherein the starch ether has hydroxyethyl substituents. 
Ploča na bazi gipsa prema zahtjevu 3, naznačena time, da škrobni eter ima hidroksietilne supstituente.
An administration port (10) according to Claim 4 wherein the outer recess formation (54) has a larger cross-sectional shape than the inner recess formation (52). 
Priključak (10) za davanje prema zahtjevu 4, naznačen time, što vanjski upust (54) ima veću površinu poprečnog presjeka od unutrašnjeg upusta (52).
An administration port (10) according to Claim 9 wherein the corresponding external cross-sectional profile of the insert member (30) extends over the engagement portion (32) and the sealing portion (34). 
Priključak (10) za davanje prema zahtjevu 9, naznačen time, što se odgovarajuća vanjska kontura poprečnog presjeka elementa (30) za uvlačenje pruža preko veznog dijela (32) i dijela za brtvljenje (34).
stirring the mixture until transformation is complete, and 
miješanje smjese dok transformacija ne bude potpuna, i
mixing Nalmefene hydrochloride (17-(cyclopropylmethyl)-4,5-a-epoxy-6-methylenemorphinan-3,14-diol hydrochloride) and aqueous solution such as water, 
miješanje nalmefen hidroklorida (17-ciklopropilmetil)-4,5-a-epoksil-6-metilenmorfinan-3,14-diol hidroklorid) i vodene otopine kao što je sama voda,
optionally, distillation of the mixture obtained in (b), 
po izboru, destiliranje smjese dobivene u (b),
cooling of the solution obtained in step (b) or (c), subsequently seeding with Nalmefene hydrochloride, and 
hlađenje otopine dobivene u (b) ili (c), nakon čega slijedi stavljanje klica nalmefen hidroklorida, i
A pharmaceutical composition comprising a compound as defined in claim 1. 
Farmaceutska smjesa koja sadrži spoj kako je definiran u zahtjevu 1.
A compound according to claim 1, for use in medicine. 
Spoj prema zahtjevu 1, za uporabu u medicini.
Amisulpride for use according to claim 1, wherein the subject of therapy is also administered an opiate. 
Amisulprid za uporabu prema zahtjevu 1, gdje liječeni bolesnik također dobiva i opijat.
Amisulpride for use according to claim 2, wherein the opiate is morphine. 
Amisulprid za uporabu prema zahtjevu 2 gdje liječeni bolesnik također dobiva i morfij.
Amisulpride for use in the therapy of opioid-induced nausea and vomiting. 
Amisulprid za uporabu u liječenju post-operativne mučnine i povraćanja.
Amisulpride for use according to claim 1, wherein the opiod is an opiate. 
Amisulprid za uporabu prema zahtjevu 1, gdje liječeni bolesnik također dobiva i opijat.
A composition comprising a compound of any one of claims 1 to 5 and a pharmaceutically acceptable carrier. 
Sastav, naznačen time, da obuhvaća spoj prema bilo kojem zahtjevu od 1 do 5 te farmaceutski prihvatljiv nosač.
overlaying the tail edge (L1) of a finished parent reel on the top of the leading edge (L2) of a new parent reel, 
prekrivanja izvodnog ruba (L1) završenog izvornog namotaja na vrhu vodećeg ruba (L2) novog izvornog namotaja,
Method according to any one of the previous claims, characterised in that said strip (S) of heat-sealing material is applied in a point of the band (W) that is positioned in an area of the completed packaging which is on the underside of the packaging. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, karakterizirana na način da je navedena traka (S) od materijala za toplinsko lijepljenje primjenjena u točki pojasa (W) koja je pozicionirana u području završenog pakiranja koje je s donje strane pakiranja.
Method according to claim 1, wherein the side of said band (W) of flexible laminated material opposite the heat-sealing side is pre-printed, said edges (L1, L2) being overlaid in such a manner that the respective printed parts are perfectly aligned, said trimming determining a perfect continuity in the printing provided on said edges (L1. L2). 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je stranica navedenog pojasa (W) fleksibilnog laminiranog materijala nasuprot toplinski ljepljive stranice predotisnuta, navedeni rubovi (L1, L2) su prekriveni na takav način da su navedeni predotisnuti dijelovi savršeno poravnati, navedeno rezanje određuje savršeni kontinuitet u otiskivanju koje se nalazi na navedenim rubovima (L1, L2).
Reel (20) according to claim 5, wherein said strip of material (S) is heat-sealing on both sides. 
Namotaj (20) u skladu s patentnim zahtjevom 5, pri čemu je navedena traka materijala (S) za toplinsko lijepljenje na obje strane.
The composition of claim 7 further comprising one or more drugs: selected from the group consisting of: anti-IgE antibody, antihistamine, bronchodilator, glucocorticoid, NSAID, TNF-antagonist, integrin antagonist, immunosuppressive agent, IL-4 antagonist, IL-13 antagonist, dual IL-4/IL-13 antagonist, DMARD, antibody that binds to a B-cell surface marker and BAFF antagonist; or 
Sastav prema zahtjevu 13, naznačen time, da nadalje obuhvaća jedan ili više lijekova odabranih iz skupine koju čine: protutijelo anti-IgE, antihistamin, bronhodilator, glukokortikoid, NSAID, TNF-antagonist, integrinski antagonist, imunosupresivno sredstvo, IL-4-antagonist, IL-13-antagonist, dvojni IL-4/IL-13-antagonist, DMARD, protutijelo koje se veže na površinski marker B-stanice i BAFF-antagonist.
the IgE-mediated disorder is selected from the group consisting of: allergic rhinitis, allergic asthma, non-allergic asthma, atopic dermatitis, allergic gastroenteropathy, anaphylaxis, urticaria, food allergies, allergic bronchopulmonary aspergillosis, parasitic diseases, interstitial cystitis, hyper-IgE syndrome, ataxia-telangiectasia, Wiskott-Aldrich syndrome, athymic lymphoplasia, IgE myeloma, graft-versus-host reaction and allergic purpura and/or 
je poremećaj, koji je posredovan s IgE, odabran iz skupine koju čine: alergijski rinitis, alergijska astma, nealergijska astma, atopički dermatitis, alergijska gastroenteropatija, anafilaksa, urtikarija, alergije na hranu, alergijska bronhopulmonarna aspergiloza, parazitne bolesti, intersticijski cistitis, hiper-IgE-sindrom, ataxia-telangiectasia, sindrom Wiskott-Aldrich, atimična limfoplazija, IgE mijelom, reakcija usatka protiv stanice domaćina i alergijska purpura, i/ili
A transgenic mouse that expresses the human M1' segment of IgE which comprises residues 317 to 351 of SEQ ID NO: 1. 
Transgenska životinja, naznačena time, da izražava humani segment M1’ od IgE, koji sadrži ostatke od 317 do 351 iz SEQ ID NO:1.
and R7 may be linked to form a ring together with the neighboring group -XA-N-XB-; 
i R7 mogu biti povezani za tvorbu prstena zajedno sa susjednom skupinom –XA-N-XB-;
XA and XB are each independently a bond, alkylene, alkenylene, -CO-, -SO2-, or -CONH-, wherein each of the alkylene and alkenylene chains can optionally contain one or more substituents selected from the group consisting of -S-, -C(=S)-, -SO2-, -CO-, -O-, -NH-, -CONH- and -SO2NH-, and the hydrogen atom (H) bonded to the nitrogen atom (N) in XA and XB is optionally substituted with a substituent selected from the group consisting of C1-6-alkyl, phenyl C1-6-alkyl and phenyl. 
XA i XB su svaki neovisno veza, alkilen, alkenilen, -CO-, -SO2-, ili -CONH-, gdje svaki od alkilen-lanaca ili alkenilen-lanaca, može po želji sadržavati jedan ili više supstituenata odabranih iz skupine koju čine: -S-, -C(=S)-, -SO2-, -CO-, -O-, -NH-, -CONH- i -SO2NH-, te kada je vodikov atom (H) spojen na dušikov atom (N) u XA i XB se po želji supstituira sa supstituentom odabranim iz skupine koju čine C1-6-alkil, fenil C1-6-alkil i fenil.
5,6,7,8-tetrahydroisoquinolyl optionally substituted with one or more oxos; 
5,6,7,8-tetrahidroizokinolil po želji supstituiran s jednom ili više okso-skupina;
3,4-dihydroisoquinolyl optionally substituted with one or more oxos; 
3,4-dihidroizokinolil po želji supstituiran s jednom ili više okso-skupina;
piperidyl optionally substituted with one or more aryl carbonyls. 
piperidil po želji supstituiran s jednom ili više aril-karbonil-skupina.
A diazepine compound or a pharmaceutically acceptable salt thereof according to claim 7, which is selected from the group consisting of the following compounds: 
Spoj diazepina ili njegova farmaceutski prihvatljiva sol prema zahtjevu 7, naznačen(a) time, da je odabran/a iz skupine koju čine sljedeći spojevi:
A pharmaceutical composition according to claim 2 for use in the prevention and/or treatment of arrhythmia. 
Farmaceutski sastav prema zahtjevu 11, naznačen time, da se upotrebljava za prevenciju i/ili liječenje aritmije.
separating the biological sample from the immobilized capture reagent; 
odvajanje biološkog uzorka iz imobiliziranog zahvaćenog reagensa;
contacting the immobilized capture reagent-target molecule complex with a detectable antibody that binds to the KDR and/or FLT1 receptor binding domains of VEGF or that binds to an epitope in VEGF1-110; and 
kontakt imobiliziranog zahvaćenog reagensa – ciljanog molekularnog kompleksa s otkrivajućim protutijelom koje se veže na KDR-receptor i/ili FLT1-receptor domene vezanja od VEGF ili koje se veže na epitop u VEGF 1-110; i
measuring the level of VEGF110+ bound to the capture reagent using a detection means for the detectable antibody. 
mjerenje razine VEGF110+ spojenog na zahvaćeni reagens uporabom sredstva za detekciju za otkrivajuće protutijelo.
The method of claim 2, wherein the human subject is a vascular, diabetic, or cancer patient and the measuring step (d) further comprises a comparison with a standard curve to determine the level of VEGF compared to a normal individual. 
Postupak prema zahtjevu 2, naznačen time, da ljudski pojedinac je vaskularni pacijent, dijabetički pacijent ili pacijent koji boluje od raka, a korak (d) nadalje obuhvaća usporedbu sa standardnom krivuljom za određivanje razine VEGF u usporedbi s istom kod zdravog pojedinca.
The method of claim 1, wherein the biological sample is tumor lysates, plasma, serum or urine. 
Postupak prema zahtjevu 1, naznačen time, da biološki uzorak je tumorski lizat, plazma, serum ili urin.
as detection reagent, a detectable antibody that binds to the KDR and/or FLT1 receptor binding domains of VEGF or that binds to an epitope in VEGF1-110. 
otkrivajuće protutijelo koje se veže na KDR-receptor i/ili FLT1-receptor domene vezanja od VEGF ili koje se veže na epitop u VEGF 1-110, kao detekcijski reagens.
Rx is -H or -C1-6alkyl; or Ri and Rx taken together with the carbon to which they are attached form a monocyclic cycloalkyl ring; and 
Rx je -H ili –C1-6alkil; ili Rj i Rx uzeti zajedno sa svojim ugljikom na koji su vezani i formiraju monociklični prsten cikloalkila;
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 2, wherein Ra and Rb are each independently-H; methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, or hexyl; an ethyl or propyl group substituted with an -OC1-4alkyl or -NRcRd substituent; or a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl, aziridinyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ6-thiomorpholin-4-yl, phenyl, or furanylmethyl group unsubstituted or substituted with a methyl or methoxy substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 2, pri čemu su Ra i Rb svaki nezavisno -H; metil, etil, propil, izopropil, butil, izobutil, sec-butil, tert-butil, pentil, izopentil, ili heksil; etil ili propil grupa supstituirana sa –OC1-4alkilom ili -NRcRd supstituentom; ili ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil, ciklopropilmetil, ciklopentilmetil, cikloheksilmetil, aziridinil, pirolidinil, tetrahidrofuranil, piperidinil, tetrahidropiranil, piperazinil, morfolinil, tiomorfolinil, 1,1-diokso-1λ6-tiomorfolin-4-il, fenil, ili furanilmetil grupa nesupstituirana ili supstituirana sa metil ili metoksi supstituentom.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, defined in claim 2, wherein Ra and Rb taken together with their nitrogen of attachment form an aziridinyl, pyrrolidinyl, piperidinyl, 2-oxo-piperidin-1-yl, piperazinyl, oxo-piperazinyl, morpholinyl, thiomorpholinyl, 1,1-dioxo-1λ6-thiomorpholin-4-yl, 1,1-dioxo-1λ6-[1,2]thiazinan-2-yl, azepanyl, 1,4-oxazepanyl, or 7-azabicyclo[2.2.1]hept-7-yl group unsubstituted or substituted with a -C1-6alkyl, hydroxymethyl, hydroxyethyl, methoxymethyl, methoxyethyl, fluoro, -OH, or -CO2H substituent. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 2, pri čemu Ra i Rb uzeti zajedno sa svojim dušikom na koji su vezani i formiraju aziridinil, pirolidinil, piperidinil, 2-okso-piperidin-1-il, piperazinil, okso-piperazinil, morfolinil, tiomorfolinil, 1,1-diokso-1λ6-tiomorfolin-4-il, 1,1-diokso-λ6-[1,2]tiazinan-2-il, azepanil, 1,4-oksazepanil, ili 7-azabiciklo[2.2.1]hept-7-il grupu nesupstituiranu ili supstituiranu sa –C1-6alkilom, hidroksimetilom, hidroksietilom, metoksimetilom, metoksietilom, fluoro, -OH, ili -CO2H supstituentom.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 2, wherein Rc and Rd taken together with their nitrogen of attachment form piperidinyl, morpholinyl, or pyrrolidinyl. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 2, pri čemu Rc i Rd uzeti zajedno sa svojim dušikom na koji su vezani i formiraju piperidinil, morfolinil, ili pirolidinil.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug, as defined in claim 1, wherein R3 is a monocyclic cycloalkyl, pyridylmethyl, benzothiadiazolyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl group unsubstituted or substituted with one, two, or three Rg substituents. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 1, pri čemu je R3 monociklični cikloalkil, piridilmetil, benzotiadiazolil, tetrahidrohinolinil, ili tetrahidroizohinolinil grupa nesupstituirana ili supstituirana sa jednim, dva, ili tri Rg supstituenta.
A compound, pharmaceutically acceptable salt or pharmaceutically acceptable prodrug as defined in claim 1, wherein Rh and Ri taken together with their nitrogen of attachment form pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski prihvatljiv prolijek, kao što je definirano u zahtjevu 1, pri čemu Rh i Ri uzeti zajedno sa svojim dušikom na koji su vezani i formiraju pirolidinil, piperidinil, piperazinil, ili morfolinil.